 |
|
Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
Deepak Mishra, Bibhuti Prassan Sinha, Mahendra Singh Kumar
Korean J Ophthalmol. 2014;28(5):399-407. Published online 2014 Sep 18 DOI: https://doi.org/10.3341/kjo.2014.28.5.399
|
|
Citations to this article as recorded by
 Efficacy and Safety of a Fixed Combination of Bimatoprost (0.03% w/v) and Timolol (0.5% w/v) for Patients with Open-angle Glaucoma
Jae Jin Cho, Jae Yeun Lee
Journal of the Korean Ophthalmological Society.2023; 64(3): 232. CrossRef Ophthalmic prostaglandin analogs revisited - A systematic review of commonly used formulations
Kaberi Biswas Feroze
Kerala Journal of Ophthalmology.2023; 35(2): 130. CrossRef Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma
Lin Zhou, Wenyi Zhan, Xin Wei
Frontiers in Pharmacology.2022;[Epub] CrossRef Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis
Jong-Wook Lee, Hyeon-Soo Ahn, Jinho Chang, Hye-Young Kang, Dong-Jin Chang, Jae Kyung Suh, Hankil Lee
Korean Journal of Ophthalmology.2022; 36(5): 423. CrossRef Effects of topical prostaglandin drops on angiogenesis in an in ovo chick chorioallantoic membrane model
Mehmet Cem Sabaner, Resat Duman, Ayhan Vurmaz, Tolga Ertekin
Cutaneous and Ocular Toxicology.2021; 40(1): 54. CrossRef Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits
Ana Marie L. Rubenicia, Leo D. P. Cubillan, Victor Arni D. P. Sicam, Allan Patrick G. Macabeo, Oliver B. Villaflores, Agnes L. Castillo
Translational Vision Science & Technology.2021; 10(4): 2. CrossRef Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Noriko Odani-Kawabata
Japanese Journal of Ophthalmology.2021; 65(6): 810. CrossRef Long-term use of latanoprost in the treatment of glaucoma
N.I. Kurysheva
Vestnik oftal'mologii.2020; 136(2): 125. CrossRef Efficacy of bimatoprost for the treatment of primary open-angle glaucoma
Hong-wei Liu, Yu-tong Lu, Yong-bo Ren, Yan Meng
Medicine.2020; 99(23): e20356. CrossRef Once-daily Preservative-free Topical Anti-glaucomatous Monotherapy – A Better Approach?
Toby S Al-Mugheiry, David C Broadway
European Ophthalmic Review.2020; 14(1): 21. CrossRef Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
Yulong Wang, Yue Liao, Xin Nie
Clinics.2020; 75: e1874. CrossRef Efficacy of travoprost for the treatment of patients with glaucoma
Xiu-Li Zhang, Li Qin
Medicine.2019; 98(29): e16526. CrossRef Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients
Wenquan Tang, Feng Zhang, Ke Liu, Xuanchu Duan
Medicine.2019; 98(30): e16597. CrossRef Topical medical therapy and ocular perfusion pressure in open angle glaucoma: a systematic review and meta-analysis
George Rennie, Angus Wilkinson, Andrew White, Marinella Ruospo, Armando Teixeira-Pinto, Giovanni Strippoli
Current Medical Research and Opinion.2019; 35(8): 1421. CrossRef Latanoprost, a balanced prostaglandin
Jose M Martinez-de-la-Casa, Shaantanu Donde, Joanna Wierzbowska
Expert Review of Ophthalmology.2019; 14(1): 61. CrossRef Effectiveness and Safety of Additive Therapy and Monotherapy of Glaucoma with Prostamides
I. R. Gazizova, S. R. Zainullina, E. B. Martynova
Ophthalmology in Russia.2019; 16(3): 366. CrossRef Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Makoto Aihara, Fenghe Lu, Hisashi Kawata, Akihiro Iwata, Kathy Liu, Noriko Odani-Kawabata, Naveed K. Shams
Journal of Glaucoma.2019; 28(5): 375. CrossRef
|